In fact, recently, RAS inhibitors (RASi) have been associated with a reduction in CV events in CML patients treated with NGTKI (Mulas et al., 2020). This evidence concerns the gene MMP19 and chronic myelogenous leukemia, BCR-ABL1 positive.